
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight Inc. has demonstrated robust revenue growth, with its recent performance exceeding consensus estimates, prompting management to raise the mid-point of its guidance for 2025. The company anticipates sustaining double-digit growth fueled by increased utilization of its light adjustable lens (LAL) technology and a growing installed base. Furthermore, RxSight has improved its gross margin expectations for 2025, which reflects a positive trajectory in financial health and operational efficiency.
Bears say
The financial performance of RxSight Inc. is concerning, with a reported revenue decline of 14% year-over-year, exacerbated by a significant drop in the monthly utilization of light adjustable lenses (LALs), which fell from 10.1 in 3Q24 to 8.0 in 3Q25. The company has also seen a drastic reduction in the placement of delivery devices (LDDs), with only 25 placed in 2Q25, marking a 68% year-over-year decrease and a 38% decline quarter-over-quarter. Further compounding these issues are risks related to limited market adoption of its product, challenges in commercial execution, intensified competition, and the potential need for dilutive financing, all of which contribute to a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares